转化生长因子β1疫苗对肝纤维化大鼠基质金属蛋白酶-2及基质金属蛋白酶组织抑制因子-2表达的影响被引量：4

Effect of TGFβ1 vaccine on the expression of MMP-2 and TIMP-2 in rats with liver fibrosis

导出

摘要转化生长因子β1（TGFβ1）是肝纤维化的启动、进展乃至肝硬化的形成中发挥核心作用的细胞因子，是激活肝星状细胞（HSC）并促进其表达细胞外基质（ECM）的关键因素。我们曾提出构建TGFβ1抗原编码序列与乙型肝炎核心抗原（HBcAg）编码序列的融合基因，将TGFβ1构建为疫苗，刺激机体产生抗体，中和自体产生的过量的TGFβ1，从而达到预防和治疗纤维化的目的。本研究旨在探讨该融合蛋白对实验性肝纤维化大鼠肝组织基质金属蛋白酶-2（MMP-2）和基质金属蛋白酶组织抑制因子-2（TIMP-2）表达的影响，以期能进一步证实TGFβ1疫苗在肝纤维化治疗中的作用，现报道如下。

作者卢明芹陈永平潘陈为王晓东

机构地区浙江省温州医学院附属第一医院感染内科

出处《中华肝脏病杂志》 CAS CSCD 北大核心 2006年第9期692-694,共3页 Chinese Journal of Hepatology

关键词肝纤维化转化生长因子Β1 疫苗基质金属蛋白酶金属蛋白酶类组织抑制剂 Liver fibrosis Transforming growth factor beta Vaccines Matrix metalloproteinases Tissue inhibitors of metalloproteinases

分类号 R575.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献2

1陈永平,潘陈为,王晓东,巩跃文,冀宏.转化生长因子β1与乙型肝炎病毒核心抗原融合基因的表达和鉴定[J].中华传染病杂志,2005,23(5):328-330. 被引量：9
2Robert Flisiak,Haza Al-Kadasi,Jerzy Jaroszewicz,Danuta Prokopowicz,Iwona Flisiak.Effect of lamivudine treatment on plasma levels of transforming growth factor β_1,tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B[J].World Journal of Gastroenterology,2004,10(18):2661-2665. 被引量：7

二级参考文献35

1Schnur J, Oláh J, Szepesi A, et al. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol, 2004, 16: 127-133.
2Kondou H, Mushiake S, Etani Y, et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol, 2003, 39:742-748.
3Yata Y, Gotwals P, Koteliansky V, et al. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor:Implications for antifibrotic therapy. Hepatology, 2002, 35:1022-1030.
4Strausberg RL, Feingold EA, Grouse LH, et al. Generation and initial analysis of more than 15 000 full-length human and cDNA sequences. Proc Natl Acad Sci USA, 2002, 99:16899-16903.
5Wei YQ, Huang MJ, Yang L, et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA, 2001,98 : 11545-11550.
6Su JM, Wei YQ, Tian L, et al. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res, 2003, 63: 600-607.
7Vernersson M, Ledin A, Johansson J, et al. Generation of therapeutic antibody responses against IgE through vaccination.Faseb J, 2002, 16: 875-877.
8Knittel T, Janneck T, Muller L, Fellmer P, Ramadori G. Transforming growth factor beta 1-regulated gene expression of Ito cells. Hepatology 1996; 24:352-360.
9Ramadori G, Saile B. The fibrogenic mediators, TGF-β and TNFa, as surviving factors for activated hepatic stellate cells. In:Gressner AM, Heirtrich PC, Matern S, eds. Cytokines in liver injury and repair. Dordrecht/Boston/London: Kluwer Academic Publishers 2002:184-188.
10Williams EJ, Gaca MD, Brigstock DR, Arthur MJ, Benyon RC.Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000;32:754-761.